Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Diabetes Tech Leade | Insulet's Omnipod system drives 30% worldwide growth, with Q1 2025 sales exceeding expectations and prompting upward revision of revenue guidance |
Market Expansion | Explore Insulet's strategic focus on the Type 2 diabetes market, representing over 30% of new customers and offering significant growth potential |
Global Reach | Delve into Insulet's international success, with recent launches in Canada and Switzerland contributing to robust growth beyond U.S. borders |
Analyst Optimism | Learn about analyst price targets ranging from $266 to $360, reflecting confidence in Insulet's market position and growth prospects |
Metrics to compare | PODD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPODDPeersSector | |
---|---|---|---|---|
P/E Ratio | 54.4x | −3.6x | −0.5x | |
PEG Ratio | 0.81 | −0.03 | 0.00 | |
Price/Book | 16.4x | 2.6x | 2.6x | |
Price / LTM Sales | 10.0x | 2.5x | 3.0x | |
Upside (Analyst Target) | 7.5% | 77.9% | 50.5% | |
Fair Value Upside | Unlock | −17.4% | 7.5% | Unlock |